Lumateperone Improves Symptoms in Patients with Bipolar Depression

In a phase 3 trial, Lumateperone was shown to improve symptoms of depression in patients with bipolar depression, according to new findings presented in a poster at Psych Congress 2022 in New Orleans, Louisiana. Lumateperone is an FDA-approved antipsychotic used to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder.

Patients with bipolar I or II disorder experiencing a major depressive episode were either given lumateperone 42mg or a placebo to take orally once daily for 6 weeks. Mean change from baseline to day 43 and shifting individual Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) item scores were analyzed. Qualifying patients were rated on the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Clinical Global Impression Scale-Bipolar Version-Severity score.

Related: FDA Approves Dissolving Sublingual Film for Agitation in Schizophrenia, Bipolar I or II

Compared to placebo, intent-to-treat patients’ MADRS scores significantly improved as well as 8 of 14 Q-LES-Q-SF items relating to functioning in daily life, including family relationships, household activities, leisure time activities, and mood.

Reference
Edwards, John, et al. Effect of Lumateperone (ITI-007) on Quality of Life and Functional Disability in the Treatment of Bipolar Depression. Poster presented at Psych Congress 2022; September 17-20, 2022.